References
- U.S. Food and Drug Administration. Daratumumab (DARZALEX). Available from https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm530249.htm. Accessed 05 February 2020.
- Morandi F, Horenstein AL, Costa F, Giuliani N, Pistoia V, Malavasi F. CD38: a target for immunotherapeutic approaches in multiple myeloma. Front Immunol 2018;9:2722.
- De Weers M, Tai YT, Van Der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011;186:1840–8.
- AABB. Mitigating the anti-CD38 interference with serological testing. AABB Assoc Bull #16-02. Bethesda, MD: AABB, 2016.
- Chapuy CI, Nicholson RT, Aguad MD, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion 2015;55:1545–54.
- Chapuy CI, Aguad MD, Nicholson RT, et al. International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing. Transfusion. 2016;56:2964–72.
- Branch DR, Muensch HA, Hian AL, Petz LD. Disulfide bonds are a requirement for Kell and Cartwright (Yta) blood group antigen integrity. Br J Haematol 1983;54:573–8.
- Carrel H, Sutor L, Leparc G, Doty M, Crews W. The long term storage effect of 0.2 M dithiothreitol on red cell antigen integrity in reagent red blood cells. Paper presented at the 2017 AABB Annual Meeting 2017.AABB.
- Lorenzen H, Lone Akhtar N, Nielsen M, Svendsen L, Andersen P. Thirty-three-day storage of dithiothreitol-treated red blood cells used to eliminate daratumumab interference in serological testing. Vox Sang 2018;113:686–93.
- Sigle JP, Mihm B, Suna R, Bargetzi M. Extending shelf life of dithiothreitol-treated panel RBC s to 28 days. Vox Sang 2018;113:397–9.
- Disbro WL. Stability guidelines for dithiothreitol-treated red blood cell reagents used for antibody detection methods in patients treated with daratumumab. Immunohematology 2017;33:105–9.
- Hugan SL, Cooling L, Larsson VM. An evaluation of storage time for dithiothreitol-treated reagent cells. Transfusion 2017; 57:2545–6.
- Scalea B. Phase III isatuximab trial meets primary endpoint of improving PFS in relapsed/refractory myeloma. Available at: https://www.targetedonc.com/news/phase-iii-isatuximab-trial-meets-primary-endpoint-of-improving-pfs-in-relapsedrefractory-myeloma. Accessed February 2020.
- Setia R, Dogra M, Sachdeva P, Handoo A, Choudhary D, Agarwal A. Daratumumab (anti-CD38) interference with serological testing: an emerging challenge for blood banks in developing countries. Glob J Transfus Med 2017;2:163–5.
- Oostendorp M, Lammerts van Bueren JJ, Doshi P, et al. When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy. Transfusion 2015;55:1555–62.
- Lippi G. Systematic assessment of the hemolysis index: pros and cons. Adv Clin Chem 2015;71:157–70.
- Chari A, Arinsburg S, Jagannath S, et al. Blood transfusion management and transfusion-related outcomes in daratumumab-treated patients with relapsed or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 2018; 18:44–51.
- Hannon JL, Clarke G. Transfusion management of patients receiving daratumumab therapy for advanced plasma cell myeloma. Transfusion 2015;55:2770.
- Tiwari AK, Aggarwal G. Daratumumab affecting the pretransfusion testing: approach to finding compatible RBC unit. Glob J Transfus Med 2017;2:166–7.